CO2020004977A2 - Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa - Google Patents
Compuestos bicíclicos para su uso como inhibidores de la ripi quinasaInfo
- Publication number
- CO2020004977A2 CO2020004977A2 CONC2020/0004977A CO2020004977A CO2020004977A2 CO 2020004977 A2 CO2020004977 A2 CO 2020004977A2 CO 2020004977 A CO2020004977 A CO 2020004977A CO 2020004977 A2 CO2020004977 A2 CO 2020004977A2
- Authority
- CO
- Colombia
- Prior art keywords
- ripi
- kinase inhibitors
- bicyclic compounds
- compounds
- ring
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570892P | 2017-10-11 | 2017-10-11 | |
| PCT/EP2018/077656 WO2019072942A1 (en) | 2017-10-11 | 2018-10-10 | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020004977A2 true CO2020004977A2 (es) | 2020-05-05 |
Family
ID=63840848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0004977A CO2020004977A2 (es) | 2017-10-11 | 2020-04-23 | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11673892B2 (enExample) |
| EP (1) | EP3694858B1 (enExample) |
| JP (1) | JP7362600B2 (enExample) |
| KR (1) | KR20200070297A (enExample) |
| CN (1) | CN111201229B (enExample) |
| AU (1) | AU2018348930A1 (enExample) |
| BR (1) | BR112020007067A2 (enExample) |
| CA (1) | CA3078653A1 (enExample) |
| CL (1) | CL2020000944A1 (enExample) |
| CO (1) | CO2020004977A2 (enExample) |
| CR (1) | CR20200151A (enExample) |
| IL (1) | IL273443A (enExample) |
| MA (1) | MA50356A (enExample) |
| MX (1) | MX2020003439A (enExample) |
| PE (1) | PE20211246A1 (enExample) |
| PH (1) | PH12020550253A1 (enExample) |
| RU (1) | RU2020114670A (enExample) |
| SG (1) | SG11202003283TA (enExample) |
| WO (1) | WO2019072942A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018100070A1 (en) | 2016-12-02 | 2018-06-07 | F. Hoffmann-La Roche Ag | Bicyclic amide compounds and methods of use thereof |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| US11072617B2 (en) | 2017-10-31 | 2021-07-27 | Genentech, Inc. | Bicyclic sulfones and sulfoxides and methods of use thereof |
| EP3908586B1 (en) | 2019-01-11 | 2022-12-21 | F. Hoffmann-La Roche AG | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
| CN114591333B (zh) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的制备方法 |
| WO2023039795A1 (zh) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1激酶抑制剂及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| AU8405691A (en) * | 1990-09-04 | 1992-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Novel tetrahydrobenzazole derivative |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| AU8071698A (en) | 1997-06-13 | 1998-12-30 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| CN102060857A (zh) | 2000-08-10 | 2011-05-18 | 辉瑞意大利有限公司 | 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物 |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| KR100861630B1 (ko) | 2001-05-24 | 2008-10-07 | 일라이 릴리 앤드 캄파니 | 제약 제제로서의 신규 피롤 유도체 |
| WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
| EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
| MX2009008546A (es) | 2007-02-07 | 2009-10-08 | Pfizer | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldehido como inhibidores de la proteina quinasa c. |
| JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| US8946266B2 (en) | 2009-07-15 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| CN103874702B (zh) | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| CN104918934B (zh) | 2013-01-18 | 2017-12-22 | 霍夫曼-拉罗奇有限公司 | 3‑取代的吡唑及其作为dlk抑制剂的用途 |
| TWI648273B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
| EA038235B1 (ru) | 2013-05-01 | 2021-07-28 | Ф.Хоффманн-Ля Рош Аг | Бигетероарильные соединения и их применения |
| EP2991977B1 (en) | 2013-05-01 | 2020-07-22 | F.Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| EP3268373B1 (en) | 2015-03-09 | 2022-04-27 | F. Hoffmann-La Roche AG | Tricyclic dlk inhibitors and uses thereof |
| PE20221048A1 (es) | 2015-07-02 | 2022-06-30 | Hoffmann La Roche | Lactamas biciclicas como inhibidores de rip1 cinasa |
| KR102808827B1 (ko) | 2016-02-05 | 2025-05-19 | 데날리 테라퓨틱스 인크. | 수용체-상호작용 단백질 키나제 1의 억제제 |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
-
2018
- 2018-10-10 MA MA050356A patent/MA50356A/fr unknown
- 2018-10-10 BR BR112020007067-0A patent/BR112020007067A2/pt not_active Application Discontinuation
- 2018-10-10 WO PCT/EP2018/077656 patent/WO2019072942A1/en not_active Ceased
- 2018-10-10 JP JP2020520532A patent/JP7362600B2/ja active Active
- 2018-10-10 CR CR20200151A patent/CR20200151A/es unknown
- 2018-10-10 CA CA3078653A patent/CA3078653A1/en active Pending
- 2018-10-10 AU AU2018348930A patent/AU2018348930A1/en not_active Abandoned
- 2018-10-10 CN CN201880066460.0A patent/CN111201229B/zh active Active
- 2018-10-10 SG SG11202003283TA patent/SG11202003283TA/en unknown
- 2018-10-10 PE PE2020000378A patent/PE20211246A1/es unknown
- 2018-10-10 RU RU2020114670A patent/RU2020114670A/ru unknown
- 2018-10-10 KR KR1020207013188A patent/KR20200070297A/ko not_active Ceased
- 2018-10-10 MX MX2020003439A patent/MX2020003439A/es unknown
- 2018-10-10 EP EP18785936.8A patent/EP3694858B1/en active Active
-
2020
- 2020-03-19 IL IL273443A patent/IL273443A/en unknown
- 2020-04-08 CL CL2020000944A patent/CL2020000944A1/es unknown
- 2020-04-09 US US16/844,952 patent/US11673892B2/en active Active
- 2020-04-09 PH PH12020550253A patent/PH12020550253A1/en unknown
- 2020-04-23 CO CONC2020/0004977A patent/CO2020004977A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7362600B2 (ja) | 2023-10-17 |
| EP3694858B1 (en) | 2023-01-11 |
| US11673892B2 (en) | 2023-06-13 |
| RU2020114670A (ru) | 2021-11-12 |
| EP3694858A1 (en) | 2020-08-19 |
| CN111201229A (zh) | 2020-05-26 |
| CA3078653A1 (en) | 2019-04-18 |
| CL2020000944A1 (es) | 2020-08-21 |
| CN111201229B (zh) | 2024-08-23 |
| WO2019072942A1 (en) | 2019-04-18 |
| MX2020003439A (es) | 2020-07-29 |
| IL273443A (en) | 2020-05-31 |
| KR20200070297A (ko) | 2020-06-17 |
| US20200283446A1 (en) | 2020-09-10 |
| JP2020536915A (ja) | 2020-12-17 |
| SG11202003283TA (en) | 2020-05-28 |
| MA50356A (fr) | 2021-04-21 |
| PH12020550253A1 (en) | 2021-02-22 |
| CR20200151A (es) | 2020-05-23 |
| BR112020007067A2 (pt) | 2020-10-06 |
| PE20211246A1 (es) | 2021-07-13 |
| AU2018348930A1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19011216A (es) | Inhibidores de piridopyrimdinona cdk2/4/6 | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CO2017011017A2 (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
| NI201800132A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| ECSP16074478A (es) | Compuestos novedosos | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| ECSP17069696A (es) | Compuestos novedosos | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| MX2018008772A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| MX2021012749A (es) | Inhibidor selectivo de la jak1 cinasa. | |
| UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| ECSP18056196A (es) | Derivados de indano | |
| ECSP13012372A (es) | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. |